Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rotation study of albuminuria-lowering drug classes in type 2 diabetes
NL-OMON47659Phase 4Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of telmisartan, empagliflozin, linagliptin and baricitinib in albuminuria and diabetic glomerulosclerosis, sponsored by University Medical Center Groningen. Primary endpoint: Degree of albuminuria lowering response across four drug classes. Started Feb 2017; status: active, not recruiting.
02
Drugs
telmisartanempagliflozinlinagliptinbaricitinib
03
Conditions
albuminuriadiabetic glomerulosclerosis
Beyond the preview
Go deeper on NL-OMON47659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47659.